OncLive TV

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

Jeanny B. Aragon-Ching, MD, FACP, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Victor M. Orellana-Noia, MD, discusses the patient population of the phase 3 POLARIX trial in diffuse large B-cell lymphoma.

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

Jeanny B. Aragon-Ching, MD, FACP, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Matthew J. Matasar, MD, discusses the unmet needs remaining in diffuse large B-cell lymphoma.

Adana A.M. Llanos, PhD, MPH, discusses disparities in genetic research in cancer care.

Matthew P. Goetz, MD, discusses the progression-free survival benefit derived with lasofoxifene in patients with ESR1-mutated, ER-positive/ HER2-negative metastatic breast cancer.

Senthil Damodaran, MD, PhD, discusses data from the phase 2 ELAINE-2 trial examining the combination of lasofoxifene and abemaciclib in patients with ESR1-mutated, estrogen receptor–positive/HER2-negative metastatic breast cancer.

Martin E. Gutierrez, MD, discusses the investigation of MK-0482 in advanced solid tumors. 

Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.

Madhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.

Andre H. Goy, MD, discusses updates in precision medicine.

Andrew Ip, MD, discusses carboplatin, pemetrexed, and pembrolizumab as first-line therapy in recurrent/metastatic non–small cell lung cancer.

James K. McCloskey, MD, discusses the efficacy of CPX-351 in FLT3-mutated acute myeloid leukemia.

Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

Sapna Patel, BA, MD, discusses the neoadjuvant administration of pembrolizumab in advanced melanoma.

Daniel P. Petrylak, MD, discusses enzalutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer.

Mohamad Ezzeddine Allaf, MD, discusses the results of perioperative nivolumab vs observation in patients with renal cell carcinoma who undergo nephrectomy.

Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Mark Yarchoan, MD, discusses the addition of durvalumab (Imfinzi) to gemcitabine and cisplatin in biliary tract cancer.

Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.

Alison K. Conlin, MD, discusses the practice-changing data of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Sameek Roychowdhury, MD, PhD, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma.

Jennifer Keating Litton, MD, discusses research areas of interest in ESR1-mutated, endocrine receptor–positive, HER2-negative breast cancer.